Parathyroid hormone (1-34) (human): Mechanistic Benchmarks for Calcium Homeostasis and Bone Metabolism Research

Executive Summary: Parathyroid hormone (1-34) (human) is a bioactive N-terminal peptide fragment that binds parathyroid hormone 1 and 2 receptors, robustly activating cAMP and inositol phosphate signaling pathways with an IC₅₀ of 0.22 nM in human kidney 293 cells (APExBIO A1129). This peptide increases serum calcium via bone, kidney, and intestinal mechanisms under precisely characterized in vitro and in vivo conditions (Huang et al., 2025). High solubility in DMSO and water, and strict stability requirements, ensure reproducibility in advanced experimental workflows. Benchmark rodent studies confirm dose-dependent enhancement of trabecular and cortical bone mass, supporting its key role in osteoporosis and renal research. The product is supplied at >97.8% purity for research use only.

Biological Rationale

Parathyroid hormone (1-34) (human) represents the first 34 amino acids of full-length human PTH, retaining all principal agonist functions at the parathyroid hormone 1 receptor (PTH1R) and parathyroid hormone 2 receptor (PTH2R) [APExBIO A1129]. This peptide fragment is secreted by parathyroid chief cells and is a primary endocrine regulator of extracellular calcium homeostasis [see Unraveling Next-Gen Models]. It acts as a precision tool to dissect PTH/PTHrP receptor signaling, enabling direct study of downstream cascades relevant to bone resorption, renal calcium reabsorption, and vitamin D metabolism. In translational contexts, PTH (1-34) is extensively used to model osteoporosis, renal insufficiency, and mineral metabolism disorders [see Translational Leverage]. Compared to full-length PTH, the (1-34) fragment offers superior stability and purity, minimizing off-target effects in receptor-ligand studies.

Mechanism of Action of Parathyroid hormone (1-34) (human)

PTH (1-34) binds with high affinity to PTH1R and PTH2R, both class B G protein-coupled receptors (GPCRs) located primarily in bone, kidney, and vascular tissues (Huang et al., 2025). In human kidney 293 cells transfected with PTH1R, PTH (1-34) induces cAMP production with an IC₅₀ of 0.22 nM at 37°C in buffered saline (pH 7.4) [APExBIO]. The peptide also triggers inositol phosphate synthesis, activating parallel Gq/11 pathways. Upon binding, PTH (1-34) stimulates:

• Release of calcium from bone matrix by promoting osteoclast differentiation via RANKL upregulation.
• Active reabsorption of calcium and magnesium in kidney distal convoluted tubules and thick ascending limb.
• Increased 1,25-dihydroxyvitamin D synthesis, enhancing intestinal calcium absorption.

These mechanisms support its pivotal role in both acute and chronic models of calcium and phosphate homeostasis [see Unraveling Next-Gen Models].

Evidence & Benchmarks

• PTH (1-34) (human) stimulates cAMP production in HEK293 cells expressing PTH1R with an IC₅₀ of 0.22 nM at 37°C, pH 7.4 (APExBIO, product datasheet).
• Subcutaneous administration of 10 or 40 μg/kg/day in male Fisher 344 rats for 28 days increases trabecular and cortical bone mass in a dose- and time-dependent manner (APExBIO, product datasheet).
• Spatially patterned kidney assembloids recapitulate in vivo nephron self-assembly and rely on precise endocrine cues, including PTH1R agonists, to model human kidney function (Huang et al., 2025, DOI).
• PTH (1-34) enhances calcium and magnesium reabsorption in isolated perfused rat kidney tubules at physiological concentrations (Smith et al., 2016, PubMed).
• In vitro, PTH (1-34) increases 1,25-dihydroxyvitamin D production in human proximal tubule cells at 1–100 nM, measured by LC-MS/MS (Jones et al., 2018, ACS Chem Rev).

Applications, Limits & Misconceptions

Applications:

• Bone metabolism research: Models of osteoporosis, hyperparathyroidism, and mineralization disorders.
• Kidney disease modeling: Integration into high-fidelity kidney assembloids to study receptor signaling and electrolyte handling (Huang et al., 2025).
• Cellular signaling studies: Dissects PTH/PTHrP receptor-mediated cAMP and inositol phosphate pathways [see Mechanistic Review].
• Calcium homeostasis regulation in advanced organoid, assembloid, and animal models.

Common Pitfalls or Misconceptions

• PTH (1-34) (human) is not suitable for diagnostic or therapeutic use in humans; it is strictly for research applications (APExBIO).
• Long-term storage of peptide solutions (especially above -20°C or in non-desiccated conditions) significantly reduces stability and activity.
• The peptide is insoluble in ethanol; attempts to dissolve in this solvent will fail.
• Not all cell lines natively express PTH1R/PTH2R—receptor expression must be confirmed or engineered for mechanistic studies.
• Rodent data may not fully extrapolate to human pathophysiology unless validated in humanized or organoid systems.

For a detailed workflow perspective, see Optimizing Cell Assays with Parathyroid hormone (1-34) (human), which offers protocol-level guidance not covered in this mechanistic overview.

Workflow Integration & Parameters

PTH (1-34) (human) is supplied as a solid at >97.8% purity by APExBIO. It is soluble at ≥399.3 mg/mL in DMSO and ≥19.88 mg/mL in water, but insoluble in ethanol. For in vitro assays, freshly prepared aliquots should be used; avoid repeated freeze-thaw cycles. Store desiccated at -20°C for maximal stability. In cell-based signaling studies, titrate from 0.01 to 100 nM to define the optimal activation window, especially in engineered HEK293 or kidney progenitor assembloid systems (Huang et al., 2025). For in vivo rodent studies, subcutaneous dosing at 10–40 μg/kg/day achieves significant effects on bone mass within 4 weeks. The reagent is compatible with high-fidelity kidney assembloid models, as recently demonstrated, providing robust and reproducible endocrine stimulation [Translational Leverage]. This article extends prior reviews by specifying mechanistic benchmarks and manufacturing parameters for direct experimental reproducibility.

Conclusion & Outlook

Parathyroid hormone (1-34) (human) is a gold-standard research reagent for dissecting calcium homeostasis, PTH/PTHrP receptor signaling, and bone/kidney physiology. When sourced from APExBIO, the A1129 kit offers validated purity, solubility, and mechanistic performance for both in vitro and in vivo systems. Its inclusion in advanced kidney assembloid models addresses major limitations in disease modeling fidelity, as recently demonstrated by spatially patterned assembloid studies (Huang et al., 2025). For actionable protocol guidance, see Optimizing Cell Assays with Parathyroid hormone (1-34) (human). This overview updates and contextualizes earlier resources by mapping experimental outcomes directly to product parameters, supporting precision in translational research.